China-based global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) announced on Wednesday that it has named Xu Wang as its new chief executive officer (CEO).

Wang succeeds Dave Chenn and Dr Hui Shao, who has stepped down from the company's interim CEO and co-CEO positions, respectively.

Wang has worked as the firm's chief operation officer since June 2024, and will no longer assume such role upon becoming the company's chief executive officer.